activ
monophosph
dehydrogenas
impdh
inhibitor
mizoribin
ribavirin
sever
acut
respiratori
syndrom
sar
associ
coronaviru
sarscov
determin
plaqu
reduct
yield
reduct
assay
mizoribin
ribavirin
select
inhibit
replic
sarscov
inhibitori
concentr
ic
mizoribin
sarscov
sarscov
determin
plaqu
reduct
gml
gml
respect
ic
ribavirin
sarscov
sarscov
gml
gml
cytotox
concentr
mizoribin
ribavirin
vero
cell
exceed
gml
yield
reduct
assay
mizoribin
gml
ribavirin
gml
inhibit
replic
sarscov
reduc
infecti
sarscov
titer
onetenth
less
mizoribin
inhibit
replic
sarscov
strongli
ribavirin
howev
neither
drug
could
complet
inhibit
replic
sarscov
even
concentr
gml
first
outbreak
sever
acut
respiratori
syndrom
sar
occur
guangdong
provinc
southern
china
novemb
spread
humantohuman
infect
area
china
well
vietnam
singapor
canada
countri
lee
et
al
poutanen
et
al
tsang
et
al
approxim
sar
patient
report
patient
die
outbreak
novemb
juli
sarsassoci
coronaviru
sarscov
identifi
caus
agent
sar
drosten
et
al
ksiazek
et
al
present
studi
inhibitori
effect
mizoribin
w
ribavirin
w
replic
sarscov
evalu
mizoribin
imidazol
nucleosid
immunosuppress
agent
use
renal
transplant
autoimmun
diseas
steroidresist
nephrot
syndrom
japan
mizoribin
phosphoryl
adenosin
kinas
convert
activ
form
mizoribin
activ
form
mizoribin
act
inhibitor
enzym
inosin
monophosph
dehydrogenas
impdh
guanosin
monophosph
synthetas
enzym
essenti
synthesi
guanosin
monophosph
inosin
monophosph
de
novo
pathway
yokota
furthermor
mizoribin
possess
vitro
antivir
activ
herp
simplex
viru
cytomegaloviru
respiratori
syncyti
viru
influenza
virus
bovin
viral
diarrhea
viru
shiraki
et
al
hosoya
et
al
shigeta
pancheva
et
al
stuyver
et
al
ribavirin
wellknown
broadspectrum
antivir
agent
ribavirin
monophosph
metabolit
ribavirin
also
act
inhibitor
impdh
mizoribin
ribavirin
suppli
yamasashouyu
co
ltd
choshi
chiba
japan
cytotox
effect
cytotox
concentr
cc
mizoribin
ribavirin
vero
cell
american
type
cell
collect
mana
cytotox
inhibitori
effect
plaqu
format
sarscov
b
plaqu
reduct
assay
inhibitori
effect
replic
sarscov
c
e
yield
reduct
assay
symbol
repres
mizoribin
ribavirin
respect
vertic
bar
indic
sd
one
hundr
percent
plaqu
number
b
correspond
control
compound
sarscov
titer
gml
drug
shown
figur
titer
significantli
differ
concentr
gml
sa
va
measur
use
cytotox
assay
kit
roch
diagnosit
mannheim
germani
accord
manufactur
instruct
cc
cc
defin
concentr
viabil
vero
cell
decreas
cell
cultur
without
addit
antivir
drug
respect
cytotox
assay
vero
cell
cultur
eagl
minimum
essenti
medium
mem
contain
fetal
bovin
serum
fb
penicillin
g
streptomycin
medium
growth
sarscov
briefli
approxim
vero
cell
per
well
inocul
well
micropl
let
stand
h
allow
cell
adher
bottom
well
cultur
medium
replac
without
drug
cell
cultur
day
co
incub
humidifi
condit
evalu
cytotox
use
kit
level
vero
cell
viabil
differ
concentr
either
drug
shown
fig
cc
mizoribin
ribavirin
exceed
gml
cc
mizoribin
ribavirin
gml
respect
present
studi
two
strain
sarscov
use
sarscov
sarscov
kindli
provid
dr
john
ziebuhr
institut
virolog
immunolog
univers
wuerzburg
wuerzburg
germani
dr
js
malik
peiri
depart
microbiolog
hong
kong
univers
hksar
respect
antisarscov
activ
drug
firstli
measur
plaqu
reduct
assay
vero
cell
vero
cell
monolay
seed
micropl
inocul
ml
sarscov
stock
solut
plaqu
format
unit
pfu
ml
incub
inocula
remov
cell
wash
phosphatebuff
salin
solut
pb
cell
cultur
design
concentr
compound
methylcellulos
h
co
incub
humidifi
condit
cultur
medium
remov
cell
cultur
plate
fix
formalin
solut
stain
crystal
violet
solut
plaqu
number
count
incub
time
set
h
plaqu
size
becam
larg
count
incub
time
set
day
experi
perform
duplic
inhibitori
concentr
ic
defin
concentr
plaqu
number
decreas
half
cell
cultur
without
addit
antivir
drug
experi
perform
three
time
independ
drug
ic
valu
calcul
averag
standard
deviat
sd
three
experi
inhibitori
concentr
ic
inhibitori
concentr
ic
determin
well
inhibitori
effect
mizoribin
ribavirin
sarscov
plaqu
format
shown
fig
respect
ic
ic
ic
valu
mizoribin
ribavirin
sarscov
shown
tabl
cytotox
concentr
duction
number
plaqu
demonstr
cell
cultur
medium
mizoribin
ribavirn
ad
howev
ic
valu
drug
could
determin
plaqu
format
sarscov
complet
inhibit
even
concentr
gml
drug
fig
shown
fig
mizoribin
inhibit
plaqu
format
sarscov
strongli
ribavirin
plaqu
reduct
assay
size
plaqu
significantli
decreas
concentr
gml
greater
drug
data
shown
inhibitori
effect
mizoribin
ribavirin
sarscov
replic
evalu
yield
reduct
assay
vero
cell
seed
micropl
inocul
sarscov
solut
h
allow
infect
sarscov
multipl
infect
moi
pfucel
h
inocula
remov
cell
wash
twice
pb
cultur
without
drug
h
time
inocul
sarscov
harvest
sampl
h
preliminari
studi
reveal
growth
sarscov
fast
daysincub
made
difficult
assess
inhibitori
effect
mizoribin
ribavirin
sarscov
replic
therefor
incub
time
set
yield
reduct
assay
medium
collect
store
c
use
stage
obviou
specif
cytopath
effect
observ
data
shown
experi
two
well
use
concentr
antivir
drug
infecti
dose
sarscov
determin
plaqu
assay
vero
cell
experi
conduct
three
time
independ
infecti
dose
calcul
averag
sd
three
independ
experi
mizoribin
inhibit
replic
sarscov
infecti
viral
dose
concentr
gml
decreas
onetenth
less
control
fig
e
inhibitori
effect
mizoribin
sarscov
replic
greater
ribavirin
fig
e
plaqu
reduct
yield
reduct
assay
demonstr
mizoribin
inhibit
replic
sarscov
strongli
ribavirin
order
determin
whether
differ
degre
inhibitori
effect
mizoribin
ribavirin
sarscov
phenomenon
observ
sarscov
inhibitori
effect
drug
replic
vaccinia
viru
lister
strain
herp
simplex
viru
type
strain
store
nation
institut
infecti
diseas
tokyo
japan
measur
control
plaqu
reduct
assay
vero
cell
report
ribavirin
inhibit
replic
vaccinia
viru
kirsi
et
al
plaqu
reduct
assay
vaccinia
viru
carri
describ
sarscov
except
length
cultur
period
plaqu
reduct
assay
vaccinia
viru
cell
cultur
day
shown
fig
ribavirin
inhibit
replic
vaccinia
viru
extent
mizoribin
howev
ribavirin
show
activ
vero
cell
mizoribin
show
inhibitori
effect
replic
fig
result
suggest
differ
degre
inhibitori
effect
viral
replic
mizoribin
ribavirin
depend
type
viru
mode
antivir
action
mizoribin
ribavirin
although
drug
act
impdh
inhibitor
outbreak
sar
sever
therapeut
strategi
treatment
sar
tri
administr
ribavirin
lopinavirritonavir
proteas
inhibitor
interferon
steroid
alon
combin
loutfi
et
al
zhao
et
al
zhaori
chu
et
al
howev
efficaci
treatment
sar
antivir
agent
develop
sever
compound
ribavirin
lopinavirritonavir
pyrazofurin
glycyrrhizin
niclosamid
antihelminth
drug
aurintricarboxyl
acid
nelfinavir
hiv
proteas
inhibitor
snitrosonacetylpenicillamin
nitric
oxid
donor
chloroquin
antimalaria
drug
demonstr
show
antisarscov
activ
vitro
chu
et
al
et
al
hensley
et
al
keyaert
et
al
sainz
et
al
stroher
et
al
wu
et
al
yamamoto
et
al
cinatl
et
al
report
ribavirin
antisarscov
activ
vitro
also
present
studi
ribavirin
complet
inhibit
replic
sarscov
even
concentr
gml
howev
ribavirin
possess
inhibitori
effect
replic
sarscov
demonstr
present
studi
well
chu
et
al
score
cytopathogen
perform
former
studi
determin
antivir
activ
test
compound
plaqu
reduct
assay
perform
present
studi
chu
et
al
reason
inhibitori
effect
ribavirin
demonstr
present
studi
previou
studi
cinatl
et
al
may
attribut
differ
procedur
use
particular
durat
incub
time
cell
presenc
ribavirin
ribavirin
phosphoryl
form
ribavirin
mono
diand
triphosph
ribavirinmonophosph
inhibit
enzymat
activ
impdh
result
decreas
intracellular
guanosin
triphosph
deoxyguanosin
triphosph
pool
level
streeter
et
al
alter
guanosin
triphosph
pool
level
caus
suppress
cellular
dna
mrna
protein
synthesi
possibl
mechan
antivir
activ
ribavirin
report
rotaviru
vesicular
stomat
viru
influenza
viru
vaccinia
viru
eriksson
et
al
low
et
al
muller
et
al
goswami
et
al
smee
et
al
kirsi
et
al
toltzi
et
al
describ
mode
antivir
action
mizoribin
consid
similar
ident
ribavirin
although
drug
act
impdh
inhibitor
mechan
antisarscov
activ
mizoribin
ribavirin
address
futur
studi
summari
mizoribin
ribavirin
possess
inhibitori
effect
replic
sarscov
vitro
antisarscov
activ
virustat
rather
virucid
find
obtain
present
studi
legitim
use
ribavirin
mizoribin
treatment
patient
sar
may
contribut
develop
antivir
agent
sarscov
therapeut
strategi
sar
